Ionis Pharmaceuticals Inc. diskutieren
Ionis Pharmaceuticals Inc.
WKN: A2ACMZ / Symbol: IONS / Name: Ionis Pharmaceuticals / Aktie / Biotechnologie & medizinische Forschung / Mid Cap /
68,00 €
0,21 %
Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) had its price target lowered by analysts at Wells Fargo & Company from $82.00 to $77.00. They now have an "overweight" rating on the stock.
Ratings data for IONS provided by MarketBeat
Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) had its price target lowered by analysts at Piper Sandler from $65.00 to $62.00. They now have an "overweight" rating on the stock.
Ratings data for IONS provided by MarketBeat
Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $60.00 price target on the stock.
Ratings data for IONS provided by MarketBeat
Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) had its "outperform" rating re-affirmed by analysts at William Blair.
Ratings data for IONS provided by MarketBeat
Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) had its "outperform" rating re-affirmed by analysts at Royal Bank of Canada. They now have a $70.00 price target on the stock.
Ratings data for IONS provided by MarketBeat
Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $60.00 price target on the stock.
Ratings data for IONS provided by MarketBeat
Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) had its "outperform" rating re-affirmed by analysts at Royal Bank of Canada. They now have a $70.00 price target on the stock.
Ratings data for IONS provided by MarketBeat
Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) had its price target lowered by analysts at Citigroup Inc. from $67.00 to $64.00. They now have a "buy" rating on the stock.
Ratings data for IONS provided by MarketBeat
Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) had its "buy" rating re-affirmed by analysts at Guggenheim.
Ratings data for IONS provided by MarketBeat
Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) is now covered by analysts at HC Wainwright. They set a "buy" rating and a $45.00 price target on the stock.
Ratings data for IONS provided by MarketBeat
Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $60.00 price target on the stock.
Ratings data for IONS provided by MarketBeat
Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $60.00 price target on the stock.
Ratings data for IONS provided by MarketBeat
Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) had its price target lowered by analysts at Needham & Company LLC from $60.00 to $55.00. They now have a "buy" rating on the stock.
Ratings data for IONS provided by MarketBeat
Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) had its price target raised by analysts at HC Wainwright from $45.00 to $50.00. They now have a "buy" rating on the stock.
Ratings data for IONS provided by MarketBeat
Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) had its price target lowered by analysts at Guggenheim from $65.00 to $64.00. They now have a "buy" rating on the stock.
Ratings data for IONS provided by MarketBeat
Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $50.00 price target on the stock.
Ratings data for IONS provided by MarketBeat
Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $50.00 price target on the stock.
Ratings data for IONS provided by MarketBeat
Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) was upgraded by analysts at Barclays PLC from an "equal weight" rating to an "overweight" rating. They now have a $57.00 price target on the stock, up previously from $51.00.
Ratings data for IONS provided by MarketBeat
Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) had its price target raised by analysts at HC Wainwright from $50.00 to $65.00. They now have a "buy" rating on the stock.
Ratings data for IONS provided by MarketBeat
Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) had its price target raised by analysts at Raymond James Financial, Inc. from $60.00 to $64.00. They now have a "strong-buy" rating on the stock.
Ratings data for IONS provided by MarketBeat
Neueste Beiträge
Jefferies_Financial_ in BankUnited Inc. diskutieren